Focus:
News
-
9 July 2020
Emergent BioSolutions and partners to develop Covid-19 therapy
Emergent BioSolutions has partnered with the Mount Sinai Health System and ImmunoTek Bio Centers for the development, manufacture and clinical testing of its Covid-19 hyperimmune globulin candidate, COVID-HIG.
-
9 July 2020
Russia approves R-Pharm’s Coronavir for Covid-19 treatment
Russian pharmaceutical company R-Pharm has secured regulatory approval for the use of its antiviral drug Coronavir, to treat patients suffering from Covid-19.
-
8 July 2020
CEPI expands Covid-19 vaccine alliance with Clover Biopharmaceuticals
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its collaboration with China-based Sichuan Clover Biopharmaceuticals to speed-up the development and manufacture of Covid-19 vaccine candidate.
-
8 July 2020
US awards $450m contract to Regeneron for Covid-19 therapy supply
Regeneron Pharmaceuticals has received a $450m contract from the US Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense for the manufacture and supply of its antibody...
-
8 July 2020
GSK partners with Medicago to develop plant-based Covid-19 vaccine
GlaxoSmithKline (GSK) has partnered with Canadian biopharmaceutical firm Medicago to develop, assess and manufacture a plant-based adjuvanted Covid-19 vaccine candidate.
-
7 July 2020
Novavax receives $1.6bn from US Government for Covid-19 vaccine
Novavax has received $1.6bn under the US Government's Operation Warp Speed (OWS) programme to support the development and manufacturing of its Covid-19 vaccine candidate.
-
7 July 2020
Mylan gets approval for emergency use of remdesivir for Covid-19
Mylan has secured regulatory approval from the Drug Controller General of India (DCGI) for restricted emergency use of 100mg/vial remdesivir lyophilized powder to treat Covid-19.
-
7 July 2020
CureVac secures European funding for infectious disease vaccines
The European Investment Bank (EIB) and European Commission have agreed to provide German company CureVac with a €75m funding for the ongoing infectious disease vaccine programmes, including its Covid-19 vaccine...
-
6 July 2020
Emergent to produce drug substance for J&Js Covid-19 vaccine
Emergent BioSolutions has entered a five-year agreement with Johnson & Johnson unit Janssen Pharmaceutical for large-scale manufacturing of drug substance for the latter's Covid-19 vaccine candidate, Ad26.COV2-S.
-
6 July 2020
Medivir and SciLifeLab partner to identify Covid-19 drug candidates
Swedish drug development company Medivir has partnered with SciLifeLab, a life science research firm, to identify compounds with the potential to inhibit SARS-CoV-2, the novel coronavirus that causes Covid-19.